Skip to main content

Table 1 Comparison between different groups of CADASIL patients

From: Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL

 No stroke (n = 16)IS only (n = 26)Ever ICH (n = 21)p value
Age (years)56.1 ± 9.259.0 ± 9.460.7 ± 9.30.22
Sex11 (68.8%)15 (57.7%)14 (66.7%)0.72
Hypertension3 (18.8%)14 (53.9%)17 (81.0%)0.001
Diabetes mellitus3 (18.8%)9 (34.6%)3 (14.3%)0.25
Hyperlipidemia7 (43.8%)9 (34.6%)9 (42.9%)0.79
Ever smoking3 (18.8%)8 (30.8%)8 (38.1%)0.47
Headache4 (25.0%)2 (15.4%)1 (7.1%)0.45
Plasma biomarkers
NfL2.53 ± 0.903.49 ± 1.383.46 ±1.240.03
GFAP4.42 ± 0.404.95 ± 1.315.89 ± 1.660.01
Tau− 0.74 ± 1.17− 0.21 ± 1.11− 0.15 ± 1.340.29
UCHL12.16 ± 0.732.40 ± 1.243.07 ± 1.660.07
Neuroimaging markers
WMH*2.2 ± 1.02.0 ± 0.92.8 ± 0.30.04
Number of lacunes*3.8 ± 4.36.2 ± 5.44.7 ± 4.60.30
Number of CMBs15.0 ± 32.214.5 ± 19.732.2 ± 29.30.02
Location of CMBs none/lobar/deep/mixed5/1/2/65/0/7/90/0/1/120.02
Follow-up
Total duration (years)2.11 ± 0.313.20 ± 1.623.78 ± 2.730.09
Recurrent stroke0 (0%)3 (11.5%)7 (33.3%)0.02
  1. Data are expressed in mean ± standard deviation or number (percentage)
  2. CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CMB cerebral microbleed, GFAP glial fibrillary acidic protein, ICH intracerebral hemorrhage, IS ischemic stroke, NfL neurofilament light chain, UCHL1 ubiquitin carboxy-terminal hydrolase L1, WMH white matter hyperintensity
  3. *n = 16, 25, and 16 for each group; n = 14, 21, and 13 for each group